RIPK1 and cholangiocarcinoma: Furthermore, targeting RIPk1/3 using CRSIPR-Cas9 system in cholangiocarcinoma established that targeting RIPK1 results in suppressed TLR3 ligand and Smac mimetic induced apoptosis and necroptosis (Lomphithak et al. 2020).